Document is current

Article History

Received: 23 May 2025

Accepted: 30 May 2025

First Online: 1 July 2025

Declarations

:

: A signed informed consent will be obtained from all patients. The study is approved by the Regional Committee for Medical and Health research in Southeast Norway (reference 606316) and the data protection office at each participating center.

: Not applicable, the manuscript does not contain any individual person’s data.

: SK: • The Norwegian Cancer Society. Study at OUS: Brain metastases in Norway– Improved classification and treatment” (2017-22), administered by PRC (paid to institution) • South-Eastern Norway Regional Health Authority. Study at OUS: Brain metastases in Norway– Improved classification and treatment” (2017-22), administered by PRC (paid to institution) • The Norwegian Cancer Society. European Palliative Care Research Centre, PRC, funded 2020-2025 (paid to institution) • Oxford Textbook of Palliative Medicine (paid to author) • EIR digital symptom assessment- License fee (paid to author) • Nutricia Norge AS. Webinar lecture, 2021 (paid to institution) • Pfizer Norge AS. Webinar lecture, 2021 (paid to institution)MGG: • South-Eastern Norway Regional Health Authority; Current colorectal cancer (CRC) challenges; increase in early-onset CRC, and oligometastatic CRC treatment and survival (PhD scholarship). • EUonQoL, EU Mission project, Co-lead WP8 (funding of WP8 • The Norwegian Cancer Society; Towards clinically useful biomarkers for colorectal cancer- a population-based Norwegian ColoRectal Registry study (project funding) • Data monitoring and ethics committee for the PLATO-trials (no payment) • Member of Norwegian Colorectal Cancer Group, and participation/editor of writing committee for Norwegian treatment guidelines for colorectal cancer and anal cancer. Faculty of Nordic Anal Cancer Group (NOAC) and International Multidisciplinary Anal Cancer Consortium (IMACC). Co-editor of ESMO Anal cancer treatment guideline 2021. Member of ESTRO, ESMO, EORTC GI group and EORTC ROSC (no payments for any) • PI in clinical trials (colorectal cancer, anal cancer) where trial drugs are provided (institutional agreements)CSN: • Astra Zeneca, speaker (paid to author) • Pfizer, lecture (paid to author) • Delphi Group Gilead (paid to institution) • Novartis advisory board (paid to author)